Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride

Pharmacopsychiatry

Volumn 45, Issue 2, 2012, Pages 57-63

  Kim, E Y ^a   Kim, S H ^a   Lee, N Y ^a   Jung, D C ^a   Kim, Y S ^a,b   Ahn, Y M ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

amisulpride; hormone related adverse effect; prolactin; schizophrenia; sexual dysfunction

Indexed keywords

AMISULPRIDE; PROLACTIN;

ADULT; AMENORRHEA; ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; LIBIDO; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; ORGASM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; THORAX; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG TOLERANCE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; REPUBLIC OF KOREA; SCHIZOPHRENIA; SELF REPORT; SEX CHARACTERISTICS; SULPIRIDE; TIME FACTORS;

EID: 84862798769     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1291175     Document Type: Article

References (43)

1. Wieck A, Haddad P M. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry: 2003; 182 199 204 (Pubitemid 36286731)
2. Haddad P M, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs: 2004; 64 2291 2314 (Pubitemid 39388605)
3. Hummer M, Huber J. Hyperprolactinemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin: 2004; 20 189 197
4. Meaney A M, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinemia. Life Sci: 2002; 71 979 992 (Pubitemid 34667104)
5. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol: 2008; 23 201 209 (Pubitemid 351577689)
6. Meltzer H Y, Goode D J, Schyve P M et al. Effect of clozapine on human serum prolactin levels. Am J Psychiatry: 1979; 136 1550 1555 (Pubitemid 10206621)
7. Small J G, Hirsch S R, Arvanitis L A et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry: 1997; 54 549 557 (Pubitemid 27258553)
8. Tollefson G D, Kuntz A J. Review of recent clinical studies with olanzapine. Br J Psychiatry Suppl: 1999; 30 35 (Pubitemid 29089309)
9. Reavley A, Fisher A D, Owen D et al. Psychological distress in patients with hyperprolactinemia. Clin Endocrinol (Oxf): 1997; 47 343 348
10. Sobrinho L G. The psychogenic effects of prolactin. Acta Endocrinol (Copenh): 1993; 129 Suppl 1 38 40 (Pubitemid 23236061)
11. Finn S E, Bailey J M, Schultz R T et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med: 1990; 20 843 848
12. Lambert M, Conus P, Eide P et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry: 2004; 19 415 422 (Pubitemid 39422495)
13. Olfson M, Uttaro T, Carson W H et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry: 2005; 66 331 338 (Pubitemid 40476756)
14. Byerly M J, Nakonezny P A, Bettcher B M et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res: 2006; 86 244 250 (Pubitemid 44234038)
15. Eberhard J, Lindstrom E, Holstad M et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand: 2007; 115 268 276 (Pubitemid 46425745)
16. Howes O D, Wheeler M J, Pilowsky L S et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry: 2007; 68 361 367 (Pubitemid 46506799)
17. Johnsen E, Kroken R A, Abaza M et al. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol: 2008; 28 686 690
18. Cutler A J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology: 2003; 28 Suppl 1 69 82 (Pubitemid 36015662)
19. Dossenbach M, Dyachkova Y, Pirildar S et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry: 2006; 21 251 258 (Pubitemid 43929245)
20. Kinon B J, Ahl J, Liu-Seifert H et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology: 2006; 31 577 588
21. Knegtering H, Boks M, Blijd C et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther: 2006; 32 315 326 (Pubitemid 43995227)
22. Liu-Seifert H, Kinon B J, Tennant C J et al. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat: 2009; 5 47 54
23. Schlosser R, Grunder G, Anghelescu I et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology: 2002; 46 33 40 (Pubitemid 35002316)
24. Bushe C, Yeomans D, Floyd T et al. Categorical prevalence and severity of hyperprolactinemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol: 2008; 22 56 62
25. Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol: 2007; 21 768 773 (Pubitemid 47437921)
26. Kopecek M, Bares M, Svarc J et al. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett: 2004; 25 419 422 (Pubitemid 40227970)
27. Paparrigopoulos T, Liappas J, Tzavellas E et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry: 2007; 31 92 96 (Pubitemid 44959254)
28. Ahn Y M, Lee K Y, Kim C E et al. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychopharmacol: 2009; 29 117 123
29. Jung H Y, Joo Y H, Shin H K et al. A validation study of Korea-version of Liverpool University neuroleptic side effect rating scale (LUNSERS). J Korean Neuropsychiatr Assoc: 2002; 41 138 145
30. Kinon B J, Gilmore J A, Liu H et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology: 2003; 28 Suppl 2 55 68 (Pubitemid 36332229)
31. Brown W A, Laughren T P. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res: 1981; 5 317 322 (Pubitemid 12181846)
32. Crawford A M, Beasley C M Jr, Tollefson G D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res: 1997; 26 41 54 (Pubitemid 27372056)
33. Faraone S V, Brown W A, Laughren T P. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. J Clin Psychiatry: 1987; 48 151 154 (Pubitemid 17063585)
34. Rao M L, Brown W A. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients. Psychopharmacology (Berl): 1987; 93 237 242 (Pubitemid 18013064)
35. Compton M T, Miller A H. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull: 2002; 36 143 164
36. Turrone P, Kapur S, Seeman M V et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry: 2002; 159 133 135
37. Kuruvilla A, Peedicayil J, Srikrishna G et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol: 1992; 19 603 606
38. Smith S M, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry: 2002; 181 49 55 (Pubitemid 34717838)
39. Wode-Helgodt B, Eneroth P, Fyro B et al. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand: 1977; 56 280 293 (Pubitemid 8190611)
40. Aizenberg D, Zemishlany Z, Dorfman-Etrog P et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry: 1995; 56 137 141
41. Knegtering H, van der Moolen A E, Castelein S et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology: 2003; 28 Suppl 2 109 123 (Pubitemid 36335820)
42. Macdonald S, Halliday J, Mac E T et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry: 2003; 182 50 56 (Pubitemid 36132419)
43. Grunder G, Wetzel H, Schlosser R et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry: 1999; 45 89 97 (Pubitemid 29049209)